STI Technology  

Sorrento Therapeutics, Inc. (STI) has one of the strongest antibody development platforms available in the industry, offering rapid development timelines and unmatched library diversity. STI’s libraries are comprised of fully human, full-length, and fully configured antibodies, designed to efficiently identify optimal antibody candidates against virtually any disease target. Importantly, STI’s technologies are unencumbered by third party royalty obligations.